Odyssey Therapeutics develops precision immunomodulators that target upstream signaling nodes in the innate immune system to prevent pathological inflammation in patients with autoimmune and inflammatory diseases. Their approach aims to achieve long-lasting remission while minimizing the risks associated with traditional immunosuppressive therapies.
Funding
$101M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune and inflammatory diseases often suppress the immune system broadly, leading to increased risk of infection and other side effects. Cytokine redundancy, where multiple cytokines drive chronic inflammation, limits the effectiveness of therapies that target only one cytokine. Existing treatments often fail to induce long-lasting remission.
Solution
Odyssey Therapeutics is developing precision immunomodulators that target upstream signaling nodes in the innate immune system to prevent pathological inflammation. By focusing on initial immune responses, their therapeutic candidates aim to stop inflammation before it starts, addressing the limitations of current therapies that target downstream inflammatory responses. This approach has the potential to induce long-lasting, deep remission while minimizing immunosuppressive risk and addressing the issue of cytokine redundancy. Odyssey is building a pipeline of small molecule and protein therapeutics designed to precisely target disease pathology.
Target Audience
The primary target audience consists of patients with autoimmune and inflammatory diseases, as well as the healthcare providers who treat them.
Features
- Small molecule and protein therapeutics pipeline
- Targets upstream signaling nodes in the innate immune system
- Focus on preventing pathological inflammation before it occurs
- Aims to induce long-lasting, deep remission
- Designed to minimize immunosuppressive risk
- Addresses cytokine redundancy